COMMUNIQUÉS West-GlobeNewswire

SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)
30/09/2025
No safety concerns or dose limiting toxicities observed SCY-247 was able to achieve target exposures at doses lower than our first-generation fungerp Safety, tolerability, and pharmacokinetic profile support the [...]
Medera Strengthens Leadership Team with Three Key Executive Appointments
30/09/2025
Clinical operations, regulatory affairs, technical expertise, and corporate leadership additions support advancing gene therapy pipeline for cardiovascular diseases BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Medera Inc [...]
gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms
30/09/2025
ROCKAWAY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer-reviewed study in Frontiers [...]
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting
30/09/2025
BERKELEY, Calif. and MAINZ, Germany, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of [...]
Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
30/09/2025
SARASOTA, FL, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery [...]
STRATA Skin Sciences Receives Continued Validation for its Personalized Approach with New Published Study Highlighting XTRAC® Excimer Laser Treatment Combined with a Topical Drug in Psoriasis
30/09/2025
HORSHAM, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]
FDA Clears OsteoProbe® (K250216): First-Ever Device Indication for Measuring Bone Material Strength
30/09/2025
SANTA BARBARA, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Active Life Scientific, Inc. (ALSI), a leader in innovative medical devices for bone quality, today announced that the U.S. Food and Drug Administration (FDA) [...]
Artelo Biosciences Announces Pricing of $2.0 Million Public Offering
30/09/2025
SOLANA BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people [...]
Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
30/09/2025
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression-Free Survival and Overall Survival FLORHAM PARK, N.J., Sept. 30, 2025 ( [...]
Cannabix Technologies Announces First Sale of BreathLogix Alcohol Screening Device to Maritime Market
30/09/2025
VANCOUVER, British Columbia, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is [...]
Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial
30/09/2025
Publication title: “Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s Disease Patients” [...]
Branded Legacy, Inc. Announces Provisional Patent Filing by BioLegacy for Disruptive Air-Driven Intranasal Platform Targeting Multi-Billion-Dollar Global Therapeutics Market
30/09/2025
Revolutionary platform aims to make life-saving overdose reversal therapies more affordable, accessible, and effective worldwide VANCOUVER, British Columbia, Sept. 30, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy [...]
Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
30/09/2025
BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update
30/09/2025
NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for [...]
Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services
30/09/2025
New Agreement with Thermo Fisher Scientific Expands Domestic Capacity to Support Future Commercial Manufacturing of Vaxcyte’s Broad-Spectrum Pneumococcal Conjugate Vaccine Candidates SAN CARLOS, Calif., Sept. 30, 2025 ( [...]
Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access
30/09/2025
Mr. Kamath brings more than 25 years of market access, pricing, and commercial operations experience to Tonix On August 15, 2025, the U.S. Food and Drug Administration approved Tonmya™ (cyclobenzaprine HCl sublingual [...]
Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)
30/09/2025
Disc is seeking accelerated approval and priority review of its NDA submission FDA decision to accept and file the NDA for review occurs within 60 days of submission WATERTOWN, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- [...]
Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device
30/09/2025
Previously Unpublished Data Confirms Vivos DNA Devices Offer a Safe and Effective Alternative Treatment for Children with ADHD and Obstructive Sleep Apnea LITTLETON, Colo., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivos [...]
Vivex Biologics Treats First Patient in its Restore Trial Evaluating VIA Disc NP™ for Patients with Degenerative Disc Disease
30/09/2025
MIAMI, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, a leader in developing and delivering innovative allografts, today announced that it has treated the first patient in its Restore U.S. clinical trial evaluating [...]

Pages